Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Managing hyponatremia in lung cancer: latest evidence and clinical implications.
Fiordoliva I, Meletani T, Baleani MG, Rinaldi S, Savini A, Di Pietro Paolo M, Berardi R. Fiordoliva I, et al. Among authors: di pietro paolo m. Ther Adv Med Oncol. 2017 Nov;9(11):711-719. doi: 10.1177/1758834017736210. Epub 2017 Oct 28. Ther Adv Med Oncol. 2017. PMID: 29344107 Free PMC article. Review.
Lynch syndrome-associated lung cancer: pitfalls of an immunotherapy-based treatment strategy in an unusual tumor type.
Maccaroni E, Lenci E, Agostinelli V, Cognigni V, Giampieri R, Mazzanti P, Di Pietro Paolo M, Bianchi F, Brugiati C, Belvederesi L, Pagliaretta S, Mandolesi A, Scarpelli M, Murrone A, Morgese F, Ballatore Z, Berardi R. Maccaroni E, et al. Among authors: di pietro paolo m. Explor Target Antitumor Ther. 2021;2(3):240-248. doi: 10.37349/etat.2021.00044. Epub 2021 Jun 28. Explor Target Antitumor Ther. 2021. PMID: 36046437 Free PMC article.
Open issues in the therapeutic management of unresectable stage III NSCLC in the immunotherapy era.
Catania C, Piperno G, Russo A, Greco C, Agustoni F, Scotti V, Proto C, Sangalli C, Patani F, Santacaterina A, Di Pietro Paolo M, Agresti B, Filippi AR, Ramella S. Catania C, et al. Among authors: di pietro paolo m. Crit Rev Oncol Hematol. 2022 Jun;174:103684. doi: 10.1016/j.critrevonc.2022.103684. Epub 2022 Apr 21. Crit Rev Oncol Hematol. 2022. PMID: 35462031 Review.
New options and open issues in the management of unresectable stage III and in early-stage NSCLC: A report from an expert panel of Italian medical and radiation oncologists - INTERACTION group.
Catania C, Filippi AR, Sangalli C, Piperno G, Russano M, Greco C, Scotti V, Proto C, Bennati C, Di Pietro Paolo M, Platania A, Olmetto E, Agustoni F, Teodorani N, Agbaje V, Russo A. Catania C, et al. Among authors: di pietro paolo m. Crit Rev Oncol Hematol. 2023 Oct;190:104108. doi: 10.1016/j.critrevonc.2023.104108. Epub 2023 Aug 24. Crit Rev Oncol Hematol. 2023. PMID: 37633350 Review.